Correlation Between Armata Pharmaceuticals and ZyVersa Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Armata Pharmaceuticals and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Armata Pharmaceuticals and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Armata Pharmaceuticals and ZyVersa Therapeutics, you can compare the effects of market volatilities on Armata Pharmaceuticals and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Armata Pharmaceuticals with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Armata Pharmaceuticals and ZyVersa Therapeutics.

Diversification Opportunities for Armata Pharmaceuticals and ZyVersa Therapeutics

0.1
  Correlation Coefficient

Average diversification

The 3 months correlation between Armata and ZyVersa is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding Armata Pharmaceuticals and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and Armata Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Armata Pharmaceuticals are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of Armata Pharmaceuticals i.e., Armata Pharmaceuticals and ZyVersa Therapeutics go up and down completely randomly.

Pair Corralation between Armata Pharmaceuticals and ZyVersa Therapeutics

Given the investment horizon of 90 days Armata Pharmaceuticals is expected to generate 0.51 times more return on investment than ZyVersa Therapeutics. However, Armata Pharmaceuticals is 1.98 times less risky than ZyVersa Therapeutics. It trades about 0.02 of its potential returns per unit of risk. ZyVersa Therapeutics is currently generating about -0.16 per unit of risk. If you would invest  232.00  in Armata Pharmaceuticals on August 27, 2024 and sell it today you would lose (3.00) from holding Armata Pharmaceuticals or give up 1.29% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Armata Pharmaceuticals  vs.  ZyVersa Therapeutics

 Performance 
       Timeline  
Armata Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Armata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Armata Pharmaceuticals is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.
ZyVersa Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Armata Pharmaceuticals and ZyVersa Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Armata Pharmaceuticals and ZyVersa Therapeutics

The main advantage of trading using opposite Armata Pharmaceuticals and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Armata Pharmaceuticals position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.
The idea behind Armata Pharmaceuticals and ZyVersa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.